U.S. Food and Drug Administration (FDA)

Telehealth access to the abortion pill mifepristone is critical for domestic violence survivors, as highlighted by personal accounts of Kaelah Oberdorf and Carrie Frail, who relied on medication abortions during abusive relationships. A Louisiana lawsuit challenges the FDA's 2023 rule allowing telehealth prescriptions, with courts temporarily blocking the rule before the Supreme Court paused the decision.

A federal appeals court blocked mail-order prescriptions of the abortion pill mifepristone, restricting access through telehealth. The 5th U.S. Circuit Court of Appeals sided with Louisiana in a lawsuit against the FDA, issuing a temporary nationwide injunction.

President Donald Trump announced a deal with Regeneron Pharmaceuticals to lower drug prices under the most-favored-nation initiative, including discounted Medicaid pricing and a $225 price for cholesterol drug Praluent on the TrumpRx website. The agreement, part of broader efforts to reduce healthcare costs ahead of midterms, also includes $27 billion in U.S. R&D investments and expedited FDA approval for Regeneron's gene therapy.

President Donald Trump signed an executive order directing the FDA to expedite the review of psychedelics designated as breakthrough therapy drugs. The order aims to accelerate access to experimental treatments for severe mental illness and depression, particularly for veterans.